PROTEONOMIX, INC. a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, is pleased to provide an update on the Company's addition to its Board of Directors. Proteonomix, Inc. is pleased to announce that Ian McNiece has been appointed to the Proteonomix Board of Directors effective today.
PROTEONOMIX, INC. (OTCBB: PROT) notes the favorable similarity between technology involved in the Cephalon, Inc. (CEPH) transaction with Australian company Mesoblast Limited.
PROTEONOMIX, INC. announced today that it has updated its corporate website (http://www.proteonomix.com) to reflect the dynamic growth and investment opportunity that exists today.
